Latest Breaking News On - ஆய்வகம் விலங்கு பராமரிப்பு சர்வதேச - Page 1 : comparemela.com

Watchdog organization alleges WSU research staff fabricated data, overdosed animals, violated protocols

An oral antisense oligonucleotide for PCSK9 inhibition

Strategies to decrease low-density lipoprotein (LDL) cholesterol could help treat atherosclerosis. Here, Gennemark et al . developed an antisense oligonucleotide (ASO) that can be delivered orally, is taken up by the liver, and targets PCSK9, which regulates the LDL receptor. Subcutaneous administration of the ASO showed high potency in mice overexpressing PCSK9, a liver half-life of 18 days in monkeys, and reduced circulating PCSK9 in humans. The oral formulation showed 5 to 7% liver bioavailability compared to subcutaneous administration in rats and dogs, and it reduced LDL cholesterol in healthy monkeys. Results support the potential of this ASO for PCSK9 inhibition while avoiding the need for injections. Inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9) reduce low-density lipoprotein (LDL) cholesterol and are used for treatment of dyslipidemia. Current PCSK9 inhibitors are administered via subcutaneous injection. We present a highly potent, chemically modified PC

The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates

Among the most promising therapeutic options for individuals with coronavirus disease 2019 (COVID-19) are monoclonal antibodies (mAbs). In this study, Jones et al . identified, characterized, and tested one such mAb, LY-CoV555, in vitro and in vivo. They found that LY-CoV555 bound to the severe acute respiratory distress syndrome coronavirus-2 (SARS-CoV-2) spike protein and prevented its interaction with angiotensin-converting enzyme 2. Prophylactic treatment with LY-CoV555 protected the upper and lower respiratory tracts of nonhuman primates from becoming infected with SARS-CoV-2. Together, these data support the clinical use of LY-CoV555 for treating patients with COVID-19. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a public health threat for which preventive and therapeutic agents are urgently needed. Neutralizing antibodies are a key class of therapeutics that may bridge widespread vaccination campaigns and offer a treatment solution in populations less res

Vyant Bio Announces Newly Appointed Board of Directors

Vyant Bio Announces Newly Appointed Board of Directors